



Company Announcements Office
Australian Stock Exchange
20 Bridge Street
Sydney NSW 2000

1 August 2014

Dear Sirs

BIOTECH CAPITAL LIMITED (BTC)

Change in Board Composition and Capital Raising

We advise that Dr Richard Treagus and Mr Peter Jones will be joining the board effective 4th August 2014, with Dr Treagus becoming Chairman.

Dr Treagus is a physician and entrepreneur, with over 20 years' experience in all aspects of the international pharmaceutical and biotechnology industry. Richard served as Chief Executive of ASX-listed company Acrux (ASX Code: ACR) until 2012, and is currently a director of QRxPharma Limited (ASX Code: QRX), and Executive Chairman of Neuren Pharmaceuticals Limited (ASX Code: NEU).

Mr Jones is a chartered accountant and was formerly a director of Investor Group Ltd (now Crowe Horwath), a listed financial services company. Peter has a strong track record as a successful investor in public and private companies and in particular has considerable investment experience in the biotechnology and life sciences sector.

With the addition of these new Directors to the Board, we advise that Mr Harry Karelis has agreed to resign as a director of the company effective from 4th August 2014. We thank Harry for his service to the Company since inception, and wish him well for his future endeavours.

The Company has agreed to immediately issue 11,183,116 shares at 2.5c per share as a placement within the company's existing placement capacity. 5,000,000 shares will be placed with Dr Treagus (and related parties) and 5,000,000 shares will be placed with Mr Jones (and related parties) as a condition of their appointment. The balance of the shares (1,183,116) will be placed with clients of Taylor Collison Limited.

The money raised (\$279,577.90 before issue expenses) will be used for working capital.

Yours faithfully

Baden M Bowen
Company Secretary